Reaction
Chronic Lymphocytic Leukaemia Refractory reporting signals
As of the last recalculation, Chronic Lymphocytic Leukaemia Refractory appears in 93 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is IBRUTINIB (PRR 169.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ibrutinib | 37 | 169.6 | 169.7 |
| Fludarabine Phosphate | 20 | 144.7 | 144.8 |
| Venetoclax | 21 | 98.3 | 98.3 |
| Obinutuzumab | 6 | 87.2 | 87.2 |